Top Medical Device Manufacturer Makes History As The First Indian Company To Make Heart Valve Technology Commercially Available
Meril Life Sciences was born with a
fundamental dedication to creating healthcare technologies that improve
the quality of human life. Our dedicated R&D team strives to be
trendsetters in product innovations by identifying unmet clinical needs
and pioneering relevant medical devices
with quick turnaround cycles. With more than 150 dedicated R&D
personnel working in a cross-functional capacity, our products form the
next generation of medical devices and therapies. Being a global medical
device manufacturer we are proud to be the first Indian company to make
Transcatheter Aortic Valve Replacement (TAVR) technology commercially available on a global scale.
Technological triumph
At Meril Life Sciences we have always been dedicated to designing and developing state-of-the-art technology to alleviate human suffering and improve quality of life. The commercial launch of the Myval TAVR technology is simply an assertion of this fundamental belief. TAVR is a minimally-invasive surgical procedure that repairs the heart valve without removing the old damaged valve. Using TAVR can help reduce hospital stay for patients, help them avoid pacemakers for upto 12 months post surgery, leave minimal scars and most importantly ensure the long term-safety and efficacy of the patient. Meril Life’s process behind creating such a technological triumph was covered by multiple news outlets and sources. A representative from the reputed website Moneycontrol.com got in touch with Mr. Sanjeev Bhatt, vice-president of corporate strategy at Meril Life Sciences to understand the hard work and effort that went into this accomplishment. As the complete article states, the market for TAVR is dominated by US medical device makers Medtronics and Edward Lifesciences, breaking into this market for an Indian company was no easy task.
Developmental challenges
“Over the last six years we have consciously decided to move into structural heart diseases. Structural heart diseases are those where people have diseases not in the vessels, but in the heart itself,” said Mr. Bhatt. One of the initial challenges we faced in this endeavour was that early heart valves were made of metal and plastic. Over a period of time, a stent that had to be permanently placed inside the heart valve began to create further complications in patients. To compete on a global scale, Meril Life Sciences developed a bioprosthetic heart valve from pericardial materials of bovine and porcine materials. This heart valve was designed to gradually dissolve for 12-24 months, thus allowing the heart to heal and function naturally, without any complications. Along with the valve, we devised a balloon delivery system and a range of accessories and paraphernalia to support the TAVR surgery.
Huge untapped market
The article further goes on to state that there are currently less than 200 TAVR procedures done in a year, even though the need for it could be around 300,000 in India alone. While the idea and execution might be spot on, there is still a need to spread awareness about TAVR to make it a common therapy for coronary artery diseases. One of the core founding principles behind Meril Life Sciences is to bring the latest technology and best procedures within the reach of the patient.
To make this goal possible we have a dedicated R&D team comprising of doctors; biomedical, electrical, chemical engineers; material science specialists; IT experts such as 3D animators; clinical and regulatory experts; IP and patent experts; manufacturing engineers; and last but not least, advertising, marketing and logistics experts. All of these aspects come together and work in a cross-functional capacity to deliver excellence in medicinal products and providing answers to some of medicine’s toughest questions.
Read full blog post here: https://www.merillife.com/blog/in-the-news/top-medical-device-manufacturer-makes-history-as-the-first-indian-company-to-make-heart-valve-technology-commercially-available
Technological triumph
At Meril Life Sciences we have always been dedicated to designing and developing state-of-the-art technology to alleviate human suffering and improve quality of life. The commercial launch of the Myval TAVR technology is simply an assertion of this fundamental belief. TAVR is a minimally-invasive surgical procedure that repairs the heart valve without removing the old damaged valve. Using TAVR can help reduce hospital stay for patients, help them avoid pacemakers for upto 12 months post surgery, leave minimal scars and most importantly ensure the long term-safety and efficacy of the patient. Meril Life’s process behind creating such a technological triumph was covered by multiple news outlets and sources. A representative from the reputed website Moneycontrol.com got in touch with Mr. Sanjeev Bhatt, vice-president of corporate strategy at Meril Life Sciences to understand the hard work and effort that went into this accomplishment. As the complete article states, the market for TAVR is dominated by US medical device makers Medtronics and Edward Lifesciences, breaking into this market for an Indian company was no easy task.
Developmental challenges
“Over the last six years we have consciously decided to move into structural heart diseases. Structural heart diseases are those where people have diseases not in the vessels, but in the heart itself,” said Mr. Bhatt. One of the initial challenges we faced in this endeavour was that early heart valves were made of metal and plastic. Over a period of time, a stent that had to be permanently placed inside the heart valve began to create further complications in patients. To compete on a global scale, Meril Life Sciences developed a bioprosthetic heart valve from pericardial materials of bovine and porcine materials. This heart valve was designed to gradually dissolve for 12-24 months, thus allowing the heart to heal and function naturally, without any complications. Along with the valve, we devised a balloon delivery system and a range of accessories and paraphernalia to support the TAVR surgery.
Huge untapped market
The article further goes on to state that there are currently less than 200 TAVR procedures done in a year, even though the need for it could be around 300,000 in India alone. While the idea and execution might be spot on, there is still a need to spread awareness about TAVR to make it a common therapy for coronary artery diseases. One of the core founding principles behind Meril Life Sciences is to bring the latest technology and best procedures within the reach of the patient.
To make this goal possible we have a dedicated R&D team comprising of doctors; biomedical, electrical, chemical engineers; material science specialists; IT experts such as 3D animators; clinical and regulatory experts; IP and patent experts; manufacturing engineers; and last but not least, advertising, marketing and logistics experts. All of these aspects come together and work in a cross-functional capacity to deliver excellence in medicinal products and providing answers to some of medicine’s toughest questions.
Read full blog post here: https://www.merillife.com/blog/in-the-news/top-medical-device-manufacturer-makes-history-as-the-first-indian-company-to-make-heart-valve-technology-commercially-available
Comments
Post a Comment